Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.03 USD
-0.05 (-1.07%)
Updated Apr 30, 2024 01:14 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Aprea Therapeutics, Inc. [APRE]
Reports for Purchase
Showing records 41 - 56 ( 56 total )
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
No Further Clarity on Clinical Holds; Reit. Neutral and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Clinical Holds Add to the Negative Sentiment for Eprenetapopt; Reit Neutral and Lowering our PT to $4 from $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold In Line With Our Expectations, Giving Eprenetapopt Another Damaging Blow
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Though Eprenetapopt Combo Hits Primary Endpoint, We Remain Guarded
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eprenetapopt Advances on Multiple Fronts, While Investors Wait For Strong Signals
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Retrospective Look at Phase 3 MDS Trial Provides Some Insights Into Recent Failure
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Aprea Faces Steep Development Climb; Reit Neutral and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
While Eprenetapopt Phase 3 Failure is Bad, Road Ahead May Be Worse; REIT Neutral and Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress Overshadowed by Risk/Reward Profile; Reit Neutral and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continue to Believe the Risk/Reward Profile Is Unfavorable; Reit Neutral and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department